On December 23, 2014, the FDA approved liraglutide, under the name Saxenda, to treat obesity, after having previously approved it under the name Victoza to treat type 2 diabetes mellitus (T2DM). As ...

In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight. If approved, ...

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and ...

GLP-1 weight loss drugs such as Ozempic and Wegovy have taken the world by storm. But some side effects, from the accepted - ...

New research reveals that liraglutide, a GLP-1 receptor agonist, crosses the blood-brain barrier to target specific neurons, reducing appetite and promoting lasting weight loss. Liraglutide, a ...

New trial shows liraglutide helps reduce BMI in children aged 6 to 12 with obesity, but side effects prompt further study Study: Liraglutide for Children 6 to <12 Years of Age with Obesity — A ...

Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of 'on treatment' type 2 ...

Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...

Liraglutide (Saxenda) added to lifestyle intervention helped reduce BMI in young children with obesity, the phase IIIa SCALE Kids trial found. By week 56, kids, ages 6 to <12 years, on once-daily 3-mg ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...